News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Medical Affairs
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics Reports Third Quarter 2018 Financial Results

Nov 08, 2018 5:05pm EST

ADMA Biologics Receives PDUFA Date for RI-002

Oct 17, 2018 7:08am EDT

ADMA Biologics Provides Regulatory Update for BIVIGAM®

Oct 11, 2018 8:48am EDT

ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center

Oct 03, 2018 7:08am EDT

ADMA Biologics Resubmits Biologics License Application for RI-002

Oct 01, 2018 7:08am EDT

ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved

Sep 05, 2018 7:08am EDT

ADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 27, 2018 7:28am EDT

ADMA Biologics Reports Second Quarter 2018 Financial Results

Aug 10, 2018 7:08am EDT

ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection

Jul 26, 2018 10:50am EDT

ADMA Biologics Receives PDUFA Date for BIVIGAM® Regulatory Submission

Jul 26, 2018 7:58am EDT
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...18
    Next
    About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

    © Copyright 2021 ADMA Biologics, Inc.
    Ramsey, NJ Offices 201-478-5552
    Boca Raton, FL Offices 561-989-5800
    info@admabio.com

    Best places to work
    Bio NJ

    2020 Innovator Award

    50 fastest companies
    2019 Fast 500 Deloitte
    Bio Florida

    Named 2019 Company of the Year